Insulin initiation in patients with type 2 diabetes mellitus: Treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analogues

European Journal of Endocrinology

Volumn 166, Issue 2, 2012, Pages 159-170

  Vaag, Allan ^a   Lund, Sørens ^b  

^a Rigshospitalet   (Denmark)

^b STENO DIABETES CENTER   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; METFORMIN; SULFONYLUREA;

BEDTIME DOSAGE; BLOOD GLUCOSE MONITORING; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DISEASE DURATION; DOSAGE SCHEDULE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG USE; EVIDENCE BASED MEDICINE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT ATTITUDE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; WEIGHT GAIN;

CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DRUG COMBINATIONS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, LONG-ACTING; PRACTICE GUIDELINES AS TOPIC;

EID: 84856104631     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-0022     Document Type: Review

References (90)

1. Klein O, Lynge J, Endahl L, Damholt B, Nosek L & Heise T. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes, Obesity & Metabolism 2007 9 290-299. (doi:10.1111/j.1463-1326.2006.00685.x)
2. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG & Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. New England Journal of Medicine 2008 358 2545-2559. (doi:10.1056/NEJMoa0802743)
3. Riddle MC, Ambrosius WT, Brillon DJ, Buse JB, Byington RP, Cohen RM, Goff DC Jr, Malozowski S, Margolis KL, Probstfield JL, Schnall A & Seaquist ER. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 2010 33 983-990. (doi:10.2337/dc09-1278)
4. Currie CJ, Peters JR, Tynan A, Evans M, Heine RJ, Bracco OL, Zagar T & Poole CD. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 2010 375 481-489. (doi:10.1016/S0140-6736(09)61969-3)
5. Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, Coresh J & Brancati FL. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. New England Journal of Medicine 2010 362 800-811. (doi:10.1056/NEJMoa0908359)
6. Nolan JJ. Consensus guidelines, algorithms and care of the individual patient with type 2 diabetes. Diabetologia 2010 53 1247-1249. (doi:10.1007/s00125-010-1767-z)
7. Schramm TK, Gislason GH, Kober L, Rasmussen S, Rasmussen JN, Abildstrom SZ, Hansen ML, Folke F, Buch P, Madsen M, Vaag A & Torp-Pedersen C. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation 2008 117 1945-1954. (doi:10.1161/CIRCULATIONAHA. 107.720847)
8. Bertram MY & Vos T. Quantifying the duration of pre-diabetes. Australian and New Zealand Journal of Public Health 2010 34 311-314. (doi:10.1111/j.1753-6405.2010.00532.x)
9. Sen K, Mukherjee AK, Dharchowdhury L & Chatterjee A. A study to find out the proportion of prediabetes in patients with acute coronary syndrome in a medical college of Kolkata. Journal of the Indian Medical Association 2008 106 776-778.
10. Valdes S, Botas P, Delgado E & Diaz CF. Mortality risk in Spanish adults with diagnosed diabetes, undiagnosed diabetes or prediabetes. The Asturias study 1998-2004. Revista Española de Cardiología 2009 62 528-534.
11. Yudkin JS, Richter B & Gale EA. Intensified glucose lowering in type 2 diabetes: time for a reappraisal. Diabetologia 2010 53 2079-2085. (doi:10.1007/s00125-010-1864-z)
12. Kilpatrick ES, Das AK, Orskov C & Berntorp K. Good glycaemic control: an international perspective on bridging the gap between theory and practice in type 2 diabetes. Current Medical Research and Opinion 2008 24 2651-2661. (doi:10.1185/03007990802347209)
13. Alvarez GF, Mavros P, Nocea G, Alemao E, Alexander CM & Yin D. Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study. Diabetes, Obesity & Metabolism 2008 10 (Suppl 1) 8-15.
14. Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, Landgraf R & Kleinebreil L. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005 28 2673-2679. (doi:10.2337/diacare.28.11.2673)
15. Rubin RR, Peyrot M, Kruger DF & Travis LB. Barriers to insulin injection therapy: patient and health care provider perspectives. Diabetes Educator 2009 35 1014-1022. (doi:10.1177/0145721709345773)
16. Davidson JA, Liebl A, Christiansen JS, Fulcher G, Ligthelm RJ, Brown P, Gylvin T & Kawamori R. Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: a meta-analysis 870. Clinical Therapeutics 2009 31 1641-1651. (doi:10.1016/j.clinthera.2009.08.011)
17. Monami M, Marchionni N & Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis 868. Diabetes Research and Clinical Practice 2008 81 184-189. (doi:10.1016/j.diabres.2008.04. 007)
18. Kilo C, Mezitis N, Jain R, Mersey J, McGill J & Raskin P. Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. Journal of Diabetes and its Complications 2003 17 307-313. (doi:10.1016/S1056-8727(03)00076-X)
19. Lund SS, Tarnow L, Frandsen M, Nielsen BB, Hansen BV, Pedersen O, Parving HH & Vaag AA. Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial. BMJ 2009 339 b4324. (doi:10.1136/bmj.b4324)
20. Garber AJ, Wahlen J, Wahl T, Bressler P, Braceras R, Allen E & Jain R. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (the 1-2-3 study). Diabetes, Obesity & Metabolism 2006 8 58-66. (doi:10.1111/j.1463-1326.2005. 00563.x)
21. Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S & Levy JC. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. New England Journal of Medicine 2007 357 1716-1730. (doi:10.1056/NEJMoa075392)
22. Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF & Paul SK. Three-year efficacy of complex insulin regimens in type 2 diabetes. New England Journal of Medicine 2009 361 1736-1747. (doi:10.1056/NEJMoa0905479)
23. Strojek K, Bebakar WM, Khutsoane DT, Pesic M, Smahelova A, Thomsen HF & Kalra S. Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT. Current Medical Research and Opinion 2009 25 2887-2894. (doi:10.1185/03007990903354674)
24. Buse JB, Wolffenbuttel BH, Herman WH, Shemonsky NK, Jiang HH, Fahrbach JL, Scism-Bacon JL & Martin SA. DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. Diabetes Care 2009 32 1007-1013. (doi:10.2337/dc08-2117)
25. Kann PH, Wascher T, Zackova V, Moeller J, Medding J, Szocs A, Mokan M, Mrevlje F & Regulski M. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Experimental and Clinical Endocrinology & Diabetes 2006 114 527-532. (doi:10.1055/s-2006-949655)
26. Jacober SJ, Scism-Bacon JL & Zagar AJ. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naive patients with type 2 diabetes receiving oral antidiabetes agents. Diabetes, Obesity & Metabolism 2006 8 448-455. (doi:10.1111/j.1463-1326.2006.00605.x)
27. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA & Yki-Jarvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005 28 254-259. (doi:10.2337/diacare.28.2.254)
28. Kazda C, Hulstrunk H, Helsberg K, Langer F, Forst T & Hanefeld M. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. Journal of Diabetes and its Complications 2006 20 145-152. (doi:10.1016/j.jdiacomp.2005.09.004)
29. Malone JK, Kerr LF, Campaigne BN, Sachson RA & Holcombe JH. Combined therapy with insulin lispro mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clinical Therapeutics 2004 26 2034-2044. (doi:10.1016/j.clinthera.2004.12.015)
30. Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P, Bode B & Garber A. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005 28 260-265. (doi:10.2337/diacare.28.2.260)
31. Lasserson DS, Glasziou P, Perera R, Holman RR & Farmer AJ. Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. Diabetologia 2009 52 1990-2000. (doi:10.1007/s00125-009-1468-7)
32. Malone JK, Bai S, CampaigneBN,Reviriego J&Augendre-Ferrante B. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with type 2 diabetes. Diabetic Medicine 2005 22 374-381. (doi:10.1111/j.1464-5491.2005.01511.x)
33. Lund SS & Vaag AA. Insulin regimens in type 2 diabetes. New England Journal of Medicine 2010 362 959. (doi:10.1056/NEJMc0911551)
34. Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A & Trautmann ME. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clinical Therapeutics 2007 29 2333-2348. (doi:10.1016/j.clinthera.2007.11.006)
35. Blickle JF, Hancu N, Piletic M, Profozic V, Shestakova M, Dain MP, Jacqueminet S & Grimaldi A. Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study. Diabetes, Obesity & Metabolism 2009 11 379-386. (doi:10.1111/j.1463-1326.2008.00980.x)
36. Blonde L, Merilainen M, Karwe V & Raskin P. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study. Diabetes, Obesity & Metabolism 2009 11 623-631. (doi:10.1111/j.1463-1326.2009.01060.x)
37. Eliaschewitz FG, Calvo C, Valbuena H, Ruiz M, Aschner P, Villena J, Ramirez LA & Jimenez J. Therapy in type 2 diabetes: insulin glargine vs, NPH insulin both in combination with glimepiride. Archives of Medical Research 2006 37 495-501. (doi:10.1016/j.arcmed.2005.10.015)
38. Esposito K, Ciotola M, Maiorino MI, Gualdiero R, Schisano B, Ceriello A, Beneduce F, Feola G & Giugliano D. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial. Annals of Internal Medicine 2008 149 531-539.
39. Fritsche A, Schweitzer MA & Haring HU. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Annals of Internal Medicine 2003 138 952-959.
40. Heine RJ, Diamant M, Mbanya JC & Nathan DM. Management of hyperglycaemia in type 2 diabetes: the end of recurrent failure? BMJ 2006 333 1200-1204. (doi:10.1136/bmj.39022.462546.80)
41. Hermansen K, Davies M, Derezinski T, Martinez RG, Clauson P & Home P. A 26-week randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006 29 1269-1274. (doi:10.2337/dc05-1365)
42. Meneghini LF, Traylor L & Schwartz S. Improved glycemic control with insulin glargine vs pioglitazone as ADD-ON therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes. Endocrine Practice 2010 16 588-599. (doi:10.4158/EP09281.OR)
43. Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL & Thorsteinsson B. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clinical Therapeutics 2006 28 1569-1581. (doi:10.1016/j.clinthera.2006.10.020)
44. Riddle MC, Rosenstock J & Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003 26 3080-3086. (doi:10.2337/diacare.26.11. 3080)
45. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C & Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008 51 408-416. (doi:10.1007/s00125-007-0911-x)
46. Standl E, Maxeiner S & Raptis S. Once-daily insulin glargine administration in the morning compared to bedtime in combination with morning glimepiride in patients with type 2 diabetes: an assessment of treatment flexibility. Hormone and Metabolic Research 2006 38 172-177. (doi:10.1055/s-2006-925222)
47. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, Vahatalo M, Virtamo H, Nikkila K, Tulokas T, Hulme S, Hardy K, McNulty S, Hanninen J, Levanen H, Lahdenpera S, Lehtonen R & Ryysy L. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006 49 442-451. (doi:10.1007/s00125-005-0132-0)
48. Miyashita Y, Nishimura R, Nemoto M, Matsudaira T, Kurata H, Yokota T, Yokota K, Tojo K, Utsunomiya K & Tajima N. Prospective randomized study for optimal insulin therapy in type 2 diabetic patients with secondary failure. Cardiovascular Diabetology 2008 7 16. (doi:10.1186/1475-2840-7-16)
49. Raskin P, Matfin G, Schwartz SL, Chaykin L, Chu PL, Braceras R & Wynne A. Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: the ACTION study (Achieving Control Through Insulin plus Oral ageNts). Diabetes, Obesity & Metabolism 2009 11 27-32. (doi:10.1111/j.1463-1326.2007.00796.x)
50. Raskin PR, Hollander PA, Lewin A, Gabbay RA, Bode B & Garber AJ. Basal insulin or premix analogue therapy in type 2 diabetes patients. European Journal of Internal Medicine 2007 18 56-62. (doi:10.1016/j.ejim.2006.09.006)
51. Ushakova O, Sokolovskaya V, Morozova A, Valeeva F, Zanozina O, Sazonova O, Zhadanova E, Starceva M, Kazakova E, Saifullina M, Shapiro I, Tarasov A, Al-Tayar B & Starkova N. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in Russia. Clinical Therapeutics 2007 29 2374-2384. (doi:10.1016/j.clinthera.2007.11.017)
52. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R & Zinman B. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009 32 193-203. (doi:10.2337/dc08-9025)
53. IDF Clinical Guidelines Task Force. Global guideline for Type 2 diabetes. Brussels: International Diabetes Federation, 2005.
54. Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, Handelsman Y, Horton ES, Lebovitz H, Levy P, Moghissi ES & Schwartz SS. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocrine Practice 2009 15 540-559.
55. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Canadian Journal of Diabetes 2008 32 S1-S201.
56. National Collaborating Centre for Chronic Conditions. Type 2 diabetes: national clinical guideline for management in primary and secondary care (update). London: Royal College of Physicians, 2008.
57. NICE short clinical guideline 87. Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes. London 2009.
58. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R & Zinman B. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009 52 17-30. (doi:10.1007/s00125-008- 1157-y)
59. Cerasi E. Comment on: Nathan DM, Buse JB, Davidson MB et al. (2006) Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 49:1711-1721. Diabetologia 2007 50 693-694. (doi:10.1007/s00125- 006-0573-0)
60. Jellinger PS, Lebovitz HE & Davidson JA. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes: response to Nathan et al. Diabetes Care 2007 30 e16-e17. (doi:10.2337/dc06-2373)
61. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R & Zinman B. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006 49 1711-1721. (doi:10.1007/s00125-006-0316-2)
62. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R & Zinman B. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006 29 1963-1972. (doi:10.2337/dc06-9912)
63. Slama G, Balkau B & Valensi P. Comment on: Nathan DM, Buse JB, Davidson MB et al. (2006) Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 49:1711-1721. Diabetologia 2007 50 1354-1355. (doi:10.1007/s00125-007-0669-1)
64. Woo V. Important differences: Canadian Diabetes Association 2008 clinical practice guidelines and the consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009 52 552-553. (doi:10.1007/s00125-008-1236-0)
65. Tibaldi J. Importance of postprandial glucose levels as a target for glycemic control in type 2 diabetes. Southern Medical Journal 2009 102 60-66. (doi:10.1097/SMJ.0b013e318188898e)
66. Monnier L, Colette C, Dunseath GJ & Owens DR. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 2007 30 263-269. (doi:10.2337/dc06-1612)
67. Del PS, Leonetti F, Simonson DC, Sheehan P, Matsuda M & DeFronzo RA. Effect of sustained physiologic hyperinsulinaemia and hyperglycaemia on insulin secretion and insulin sensitivity in man. Diabetologia 1994 37 1025-1035. (doi:10.1007/BF00400466)
68. Garber AJ, Ligthelm R, Christiansen JS & Liebl A. Premixed insulin treatment for type 2 diabetes: analogue or human? Diabetes, Obesity & Metabolism 2007 9 630-639. (doi:10.1111/j.1463-1326.2006.00654.x)
69. Liebl A, Prager R, Binz K, Kaiser M, Bergenstal R & Gallwitz B. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER study: a randomized controlled trial. Diabetes, Obesity & Metabolism 2009 11 45-52. (doi:10.1111/j.1463-1326.2008.00915.x)
70. Yoshioka N, Kurihara Y, Manda N, Komori K, Kato M, Kijima H, Wada N, Yanagisawa K, Aoki S, Ono Y & Koike T. Step-up therapy with biphasic insulin aspart-70/30-Sapporo 1-2-3 study. Diabetes Research and Clinical Practice 2009 85 47-52. (doi:10.1016/j.diabres.2009.04.012)
71. Cohen D & Carter P. How small changes led to big profits for insulin manufacturers. BMJ 2010 341 c7139. (doi:10.1136/bmj.c7139)
72. Currie CJ, Gale EA & Poole CD. Estimation of primary care treatment costs and treatment efficacy for people with type 1 and type 2 diabetes in the United Kingdom from 1997 to 2007. Diabetic Medicine 2010 27 938-948. (doi:10.1111/j.1464-5491.2010.03040.x)
73. The State of Healthcare Quality 2008, 2010.
74. Simons WR, Vinod HD, Gerber RA & Bolinder B. Does rapid transition to insulin therapy in subjects with newly diagnosed type 2 diabetes mellitus benefit glycaemic control and diabetes-related complications? A German population-based study. Experimental and Clinical Endocrinology & Diabetes 2006 114 520-526. (doi:10.1055/s-2006-951779)
75. Ringborg A, Lindgren P, Yin DD, Martinell M & Stalhammar J. Time to insulin treatment and factors associated with insulin prescription in Swedish patients with type 2 diabetes. Diabetes and Metabolism 2010 36 198-203.
76. Davis TM, Davis Cyllene Uwa Edu Au WA & Bruce DG. Glycaemic levels triggering intensification of therapy in type 2 diabetes in the community: the Fremantle Diabetes Study. Medical Journal of Australia 2006 184 325-328.
77. Donnan PT, Steinke DT, Newton RW & Morris AD. Changes in treatment after the start of oral hypoglycaemic therapy in type 2 diabetes: a population-based study. Diabetic Medicine 2002 19 606-610. (doi:10.1046/j.1464- 5491.2002.00743.x)
78. Rubino A, McQuay LJ, Gough SC, Kvasz M & Tennis P. Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with type 2 diabetes: a population-based analysis in the UK. Diabetic Medicine 2007 24 1412-1418. (doi:10.1111/j.1464-5491.2007.02279.x)
79. Polonsky WH, Fisher L, Guzman S, Villa-Caballero L & Edelman SV. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care 2005 28 2543-2545. (doi:10.2337/diacare.28.10.2543)
80. Aschner P, LaSalle J & McGill M. The team approach to diabetes management: partnering with patients. International Journal of Clinical Practice 2007 61 22-30. (doi:10.1111/j.1742-1241.2007.01606.x)
81. Serrano-Gil M & Jacob S. Engaging and empowering patients to manage their type 2 diabetes. Part I: a knowledge, attitude, and practice gap? Advances in Therapy 2010 27 321-333. (doi:10.1007/s12325-010-0034-5)
82. Rubin RR. Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. American Journal of Medicine 2005 118 (Suppl 5A) 27S-34S. (doi:10.1016/j.amjmed.2005.04.012)
83. Peyrot M, Rubin RR, Kruger DF & Travis LB. Correlates of insulin injection omission. Diabetes Care 2010 33 240-245. (doi:10.2337/dc09-1348)
84. Dale J, Martin S & Gadsby R. Insulin initiation in primary care for patients with type 2 diabetes: 3-year follow-up study. Primary Care Diabetes 2010 4 85-89. (doi:10.1016/j.pcd.2010.03.001)
85. Claxton AJ, Cramer J & Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clinical Therapeutics 2001 23 1296-1310. (doi:10.1016/S0149-2918(01)80109-0)
86. Kennedy L, Herman WH, Strange P & Harris A. Impact of active versus usual algorithmic titration of basal insulin and point-of- care versus laboratory measurement of HbA1c on glycemic control in patients with type 2 diabetes: the Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial. Diabetes Care 2006 29 1-8. (doi:10.2337/diacare.29.01.06.dc05- 1058)
87. Davies MJ, Donnelly R, Barnett AH, Jones S, Nicolay C & Kilcoyne A. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. Diabetes, Obesity & Metabolism 2009 11 1153-1162. (doi:10.1111/j.1463-1326.2009.01154.x)
88. Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C & Linn T. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 2008 371 1073-1084. (doi:10.1016/S0140- 6736(08)60485-7)
89. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH & Brodows RG. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Annals of Internal Medicine 2005 143 559-569.
90. Bebakar WM, Chow CC, Kadir KA, Suwanwalaikorn S, Vaz JA & Bech OM. Adding biphasic insulin aspart 30 once or twice daily is more efficacious than optimizing oral antidiabetic treatment in patients with type 2 diabetes. Diabetes, Obesity & Metabolism 2007 9 724-732. (doi:10.1111/j.1463-1326. 2007.00743.x)